Identification of TP53 gene mutations in uterine corpus cancer with short follow-up.
The involvement of the TP53 tumor suppressor gene in uterine corpus cancer was investigated by single-stranded conformation polymorphism and sequence analysis of its exons 4 to 10. Mutations were found in 12 (18.5%) of 65 cases. Ten of these 12 were single-base substitutions (8 missense and 2 nonsense mutations), whereas 2 were frame-shifting mutations. TP53 gene mutations correlated significantly with advanced surgical stage of disease (P = 0.006) and unfavorable tumor histology types (P = 0.003), whereas the association to myometrial wall invasion did not reach statistical significance (P = 0.054). TP53 gene mutations also correlated significantly with allelic loss at TP53 locus (P = 0.024), absence of estrogen (P = 0.045) and progesterone receptors (P = 0.001), DNA nondiploidy (P = 0.002), and high S-phase fraction values (P = 0.002). Our results suggest that inactivation of the TP53 checkpoint function is associated with disease transition into a stage of rapid progression and spread.
Koul
A
A
Jubileum Institute, Department of Oncology, University Hospital, Lund, Sweden.
Borg
A
A
Pejovic
T
T
Bendahl
P O
PO
Högberg
T
T
Iosif
C S
CS
Killander
D
D
D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D017931:DNA Primers; D004273:DNA, Neoplasm; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D011003:Ploidies; D016133:Polymerase Chain Reaction / Q000379:methods; D018807:Polymorphism, Single-Stranded Conformational; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014594:Uterine Neoplasms / Q000235:genetics*
D017931:DNA Primers; D004273:DNA, Neoplasm; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone